America is reeling from interconnected crises: the public health crisis of the coronavirus pandemic and the societal crisis of police brutality and systemic racism. Now is the time to heal the root causes of the systemic ills that plague us.
Remdesivir authorizations provide COVID-19 treatment hope, but illustrate hurdles to equitable patient access
The case of remdesivir illustrates that various hurdles in licensing, manufacturing, and distribution must be overcome to ensure adequate and equitable access to treatments, vaccines, diagnostics, and other medical equipment for COVID-19. There is a growing consensus among political leaders and civil society that COVID-19 medical products are global public goods and must be made available to all globally who need them. No country is safe from COVID-19 until all are safe.
COVID-19 Pandemic Reveals Current Weaknesses in U.S. Biopreparedness
The ongoing coronavirus disease (COVID-19) pandemic reveals shortcomings in U.S. pandemic preparedness under the Trump administration. The federal government must accelerate its response and marshal available resources to help state and local governments develop medical surge capacity and support community mitigation strategies.
Elimination of Cervical Cancer as a Global Public Health Problem
On this year’s World Cancer Day, February 4, 2020, it is particularly fitting that the Executive Board of the World Health Organization (WHO) is meeting to review a draft global strategy to accelerate the elimination of cervical cancer as a global public health problem.
Time to Invest in Tuberculosis Research and Development
Innovative TB medical products are needed in low-incidence and high-incidence countries alike to support patient-centered care for TB patients and advance toward global TB elimination. If world leaders are serious about the commitments made to ending the global TB epidemic at the UN High-level Meeting in September 2018, investments in TB R&D must match the rhetoric.